Survival outcome and impact of delayed imatinib therapy in gastric gastrointestinal stromal tumors
Delayed imatinib therapy negatively impacts DFS in high-risk gastric GIST patients, highlighting the need for improved access to early TKI treatment. Additionally, smoking cessation and optimized perioperative management may enhance survival outcomes. Addressing modifiable risk factors and ensuring timely posoperative treatment could improve prognosis in this population.
Authors
- Wongsakorn Chaochankit (ORCID: https://orcid.org/0000-0003-2202-7426)
- Srila Samphao
- R. Jansuwan
Institutions
- Prince of Songkla University (TH)
Publication Details
- Journal
- Frontiers in Surgery
- Published
- 2025-04-03
- DOI
- https://doi.org/10.3389/fsurg.2025.1569677
- Primary Topic
- Gastrointestinal Tumor Research and Treatment
- Type
- article
- Field-Weighted Citation Impact
- 0.00